Female Infertility Market Analysis, Size, Share & Growth Forecast 2026–2034

GnRH Antagonist Cetrorelix and Ganirelix Immediate Pituitary Suppression Without LH Flare and Shorter Total Stimulation Cycle Versus GnRH Agonist 2 to 4-Week Down-Regulation Has Established the Antagonist Protocol as the Simplified Shorter ART Standard That Avoids the Agonist Initiation Flare.Biosimilar follitropin alpha and choriogonadotropin alfa from Merck KGaA, Ferring Pharmaceuticals, and IBSA have entered European and emerging markets at 25-40% price reductions, and the Gedeon Richter Bemfola and Teva Pharmaceutical Ovaleap biosimilars have demonstrated pharmacokinetic and clinical equivalence to reference Gonal-F in EU-approved biosimilar switching studies. The US biosimilar gonadotropin market remains less developed than Europe due to the regulatory complexity of comparative clinical data requirements for complex peptide hormones, but FDA approvals of biosimilar follitropin are expected to accelerate following the 2024 guidance update on protein biosimilar extrapolation principles. The per-IVF-cycle gonadotropin cost reduction from biosimilar competition has contributed to the gradual improvement in IVF access in markets where treatment cost is the primary barrier to fertility care, alongside insurance mandate expansions in 20 US states that provide IVF coverage for a growing proportion of affected couples.

Follitropin Delta Rekovelle AMH and Body Weight Individualised Dosing CITRUS Phase III Comparable Live Birth Rate With Reduced OHSS in High-Responder Has Established the Precision ART Stimulation That Replaces Fixed-Dose FSH With the Individualised Response Prediction.PGT-A screening for aneuploidy has been demonstrated to increase per-transfer live birth rate from approximately 35% to 50-60% in women under 35 by selecting euploid embryos for transfer that are more likely to implant and less likely to miscarry than aneuploid embryos identified by chromosomal microarray or next-generation sequencing. The combination of PGT-A with elective single embryo transfer has reduced the multiple pregnancy rate in IVF from over 30% to under 5% in leading IVF centres that have fully adopted eSET protocols, eliminating the twin and triplet complications that were the most significant adverse outcomes of IVF in the multiple embryo transfer era. The commercial PGT-A market from CooperSurgical Genomics, Igenomix, and Natera generates approximately USD 1,500-2,000 per cycle in testing fees that add to the IVF cycle cost but are justified by the improved per-transfer success rate that reduces the total number of cycles required to achieve live birth.

Freeze-All IVF Strategy Freezing All Embryos for Subsequent Natural or Programmed FET Cycle Preventing OHSS in High-Responders and the Supraphysiological Oestrogen Uterine Receptivity Impairment Has Established the Safety and Receptivity Optimisation Rationale for Elective Embryo Cryopreservation.Vitrification rapid-freeze technology achieving above 90% oocyte survival after thaw has replaced slow-freeze protocols with less than 70% survival, and ASRM's 2013 removal of the experimental label from oocyte cryopreservation validated the clinical evidence base for fertility preservation in cancer patients and elective social egg freezing. The commercial elective egg-freezing market generating approximately USD 10,000-15,000 per cycle in the US has attracted venture-backed fertility clinic chains including Kindbody, Extend Fertility, and Shady Grove Fertility that have standardised egg-freezing programmes and are pursuing employer benefit partnerships that cover egg-freezing costs as a recruitment and retention benefit for working women. Long-term follow-up of thaw cycles from elective egg-freezing cohorts is establishing the age-stratified live birth rates that inform evidence-based counselling, with 35-year-old women storing 15-20 mature oocytes achieving cumulative live birth rates of approximately 70-75% if all stored oocytes are eventually utilised for fertility treatment.

For related market intelligence, see the Endometriosis Market.